{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:44Z","timestamp":1792798784482,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08281-2","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:56:40Z","timestamp":1792753000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained increases in lumbar spine and hip BMD with denosumab therapy beyond 10 years"],"prefix":"10.1007","author":[{"given":"Finlay","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaleen","family":"Lannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9809-1014","authenticated-orcid":false,"given":"Kevin","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"8281_CR1","unstructured":"U.S. Food and Drug Administration (2011) Prolia (denosumab) injection, for subcutaneous use: prescribing information. Silver Spring (MD): FDA Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125320s5s6lbl.pdf"},{"key":"8281_CR2","unstructured":"Denosumab in postmenopausal women: Estimates of patients treated reflect global data since launch (June 2010-June 2024; US=approximately 25% of data): https:\/\/www.proliahcp.com\/"},{"issue":"7","key":"8281_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diab Endocrinol 5(7):513\u2013523 https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diab Endocrinol"},{"key":"8281_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117600","volume":"200","author":"AM Naciu","year":"2025","unstructured":"Naciu AM, Tabacco G, Palermo A, Yavropoulou MP, Rolvien T et al (2025) Treating osteoporosis with denosumab or bisphosphonates in the long term: facts, uncertainties and assumptions. A narrative review by the clinical action group of the European Calcified Tissue Society (ECTS). Bone 200:117600 https:\/\/doi.org\/10.1016\/j.bone.2025.117600","journal-title":"Bone"},{"issue":"3","key":"8281_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.11005\/jbm.2024.31.3.246","volume":"31","author":"J Lee","year":"2024","unstructured":"Lee J, Lee YJ, Ha J (2024) Denosumab in osteoporosis: predicting long-term efficacy beyond 10 years. J Bone Metab 31(3):246\u2013249 https:\/\/doi.org\/10.11005\/jbm.2024.31.3.246","journal-title":"J Bone Metab"},{"issue":"10","key":"8281_CR6","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","volume":"109","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M et al (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than a single infusion? J Clin Endocrinol Metab 109(10):e1817\u2013e1826 https:\/\/doi.org\/10.1210\/clinem\/dgae224","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8281_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3803\/EnM.2024.2125","volume":"40","author":"J Ha","year":"2025","unstructured":"Ha J, Lee YJ, Kim J, Jeong C, Lim Y, Lee J, Baek KH (2025) Long-term efficacy and safety of denosumab: insights beyond 10 Years of Use. Endocrinol Metab 40(1):47\u201356 https:\/\/doi.org\/10.3803\/EnM.2024.2125","journal-title":"Endocrinol Metab"},{"issue":"Issue 5","key":"8281_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 104(Issue 5):1595\u20131622 https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"8281_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105954","volume":"93","author":"Y Degbo\u00e9","year":"2025","unstructured":"Degbo\u00e9 Y, Couture G (2025) Strategies for denosumab discontinuation in postmenopausal osteoporosis. Jt Bone Spine 93(2):105954 https:\/\/doi.org\/10.1016\/j.jbspin.2025.105954","journal-title":"Jt Bone Spine"},{"issue":"9999","key":"8281_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u20131155 https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"3","key":"8281_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/pcan.2012.18","volume":"15","author":"RB Egerdie","year":"2012","unstructured":"Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C (2012) Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 15(3):308\u2013312 https:\/\/doi.org\/10.1038\/pcan.2012.18","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8281_CR12","doi-asserted-by":"publisher","first-page":"101847","DOI":"10.1016\/j.bonr.2025","volume":"25","author":"S Kumar","year":"2025","unstructured":"Kumar S, Streeter C, McDonald MM, Clifton-Bligh RJ, Gild ML, Girgis CM (2025) Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomes. Bone Rep 25:101847 https:\/\/doi.org\/10.1016\/j.bonr.2025","journal-title":"Bone Rep"},{"key":"8281_CR13","doi-asserted-by":"publisher","unstructured":"Adami G, Pollastri F, Fassio A, Montanari F, Piccinelli A, Benini C, Pasetto E, Dartizio C, Gatti D, Rossini M, Viapiana O (2025) Romosozumab and denosumab combination therapy after denosumab in postmenopausal osteoporosis. Arthritis Rheumatol https:\/\/doi.org\/10.1002\/art.70002","DOI":"10.1002\/art.70002"},{"issue":"10","key":"8281_CR14","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan De Beur S, Langdahl B, Rhee Y, Fuleihan GE, Kiel DP, Schousboe JT, Borges JL, Cheung AM, Diez-Perez A, Hadji P, Tanaka S, Thomasius F, Xia W, Cummings SR (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Min Res 39(10):1393\u20131405 https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Min Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08281-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08281-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08281-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:30Z","timestamp":1792796610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08281-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":14,"alternative-id":["8281"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08281-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Finlay Brennan, Donal Fitzpatrick, Rosaleen Lannon and Kevin McCarroll have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}